Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Curran

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
ACS Chemical Biology|May 25, 2022
Directed Evolution of PD-L1-Targeted Affibodies by mRNA DisplayBrian J Grindel, Brian J Engel, Justin N Ong, et al.
Journal for Immunotherapy of Cancer|October 4, 2023
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunityPaul Koller, Natalia Baran, Karine Harutyunyan, et al.
Journal for Immunotherapy of Cancer|August 3, 2021
High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilegeCasey R Ager, Akash Boda, Kimal Rajapakshe, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 1, 2002
Expression from second-generation feline immunodeficiency virus vectors is impaired in human hematopoietic cellsMary A Price, Scott S Case, Denise A Carbonaro, et al.
The Journal of Clinical Investigation|September 7, 2018
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapyPriyamvada Jayaprakash, Midan Ai, Arthur Liu, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 22, 2012
Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer modelYohei Mineharu, A K M Ghulam Muhammad, Kader Yagiz, et al.
Neuro-Oncology|January 27, 2023
Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human diseaseChao-Hsien Chen, Renee L Chin, Genevieve P Hartley, et al.
Science Translational Medicine|October 26, 2018
Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinomaLiran Zhou, Hongmei Husted, Todd Moore, et al.
Clinical and Molecular Hepatology|July 22, 2024
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trialSun Young Yim, Sung Hwan Lee, Seung-Woo Baek, et al.
Clinical and Molecular Hepatology|February 27, 2025
Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823]Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
ACS Chemical Biology|May 25, 2022
Directed Evolution of PD-L1-Targeted Affibodies by mRNA DisplayBrian J Grindel, Brian J Engel, Justin N Ong, et al.
Journal for Immunotherapy of Cancer|October 4, 2023
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunityPaul Koller, Natalia Baran, Karine Harutyunyan, et al.
Journal for Immunotherapy of Cancer|August 3, 2021
High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilegeCasey R Ager, Akash Boda, Kimal Rajapakshe, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 1, 2002
Expression from second-generation feline immunodeficiency virus vectors is impaired in human hematopoietic cellsMary A Price, Scott S Case, Denise A Carbonaro, et al.
The Journal of Clinical Investigation|September 7, 2018
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapyPriyamvada Jayaprakash, Midan Ai, Arthur Liu, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 22, 2012
Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer modelYohei Mineharu, A K M Ghulam Muhammad, Kader Yagiz, et al.
Neuro-Oncology|January 27, 2023
Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human diseaseChao-Hsien Chen, Renee L Chin, Genevieve P Hartley, et al.
Science Translational Medicine|October 26, 2018
Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinomaLiran Zhou, Hongmei Husted, Todd Moore, et al.
Clinical and Molecular Hepatology|July 22, 2024
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trialSun Young Yim, Sung Hwan Lee, Seung-Woo Baek, et al.
Clinical and Molecular Hepatology|February 27, 2025
Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823]Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, et al.
Pageof 9